To experimentally validate the SARS-CoV-2 specific T-cell immunity in the COVID-19 convalescent patients, we synthesized 276 potential T-cell epitope peptides from all the 29 proteins of SARS-CoV-2,37–39 with 210 corresponding to HLA class I CD8+ T-cell epitopes and 66 to HLA class II CD4+ T-cell epitopes (Fig. 5a). This evidence concerns the gene CD8A and COVID-19.